Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG-BM1 in Moderate-to-Severe Acute Respiratory Distress Syndrome
NCT07892950Phase 1Completed
- Sponsor
- Guangzhou Saijun Biotechnology Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of CG-BM1 in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Guangzhou Saijun Biotechnology Co., Ltd. Primary endpoints: Incidence of Dose-Limiting Toxicity at 14 days and Incidence of Adverse Events and Serious Adverse Events at 6 months. Started Jan 2023; status: completed.
02
Drugs
CG-BM1
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07892950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892950.